FiercePharma12d
Novo asks FDA to restrict Victoza compounding amid GLP-1 outsourcing row
In a citizen petition posted by the FDA this week, Novo urged the regulator to restrict the ability of compounding pharmacies ...
Community Impact Newspaper5d
Houston-area health care providers see rising demand for diabetes, obesity drugs
A new request by Ozempic manufacturer Novo Nordisk could limit the availability of a type of GLP-1—semaglutides—to local ...
Seeking Alpha13d
Lilly seeking to join lawsuit over compounded GLP-1 drugs
Tirzepatide and semaglutide both belong to a class of drugs known as GLP-1s. Compounding pharmacies have been producing copycat versions of the drugs while they have been in short supply.
CNBC on MSN22d
FDA says the Zepbound shortage is over. Here's what that means for compounding pharmacies, patients who used off-brand versions
Many compounding pharmacies make unbranded versions of semaglutide, which has been on the U.S. market — and in short supply — ...
pharmaphorum1d
Novo joins Lilly in asking FDA for ban on GLP-1 compounding
Novo Nordisk has asked the FDA to stop compounding pharmacies making cheaper versions of its semaglutide-based therapies for obesity and diabetes, saying the drug is too complex to be made safely ...
NBC New York23d
FDA says the Zepbound shortage is over. Here's what that means for compounding pharmacies, patients who used off-brand versions
Many compounding pharmacies make unbranded versions of semaglutide, which has been on the U.S. market — and in short supply — for much longer than tirzepatide. But an end to the shortage may ...